Essentially, the effects of SGLT-2 inhibitors, which include the inhibition of cancer cell proliferation, have been demonstrated in in vitro studies, which have often used higher concentrations of these drugs than the maximum blood serum concentrations in patients using SGLT-2 inhibitors for diabetes or heart failure. Here, SLC5A2 is linked to cancer.